Compare BDSX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | NYXH |
|---|---|---|
| Founded | 2005 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.2M | 134.5M |
| IPO Year | 2020 | 2021 |
| Metric | BDSX | NYXH |
|---|---|---|
| Price | $14.59 | $2.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $9.33 |
| AVG Volume (30 Days) | ★ 64.7K | 32.9K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | N/A |
| Revenue This Year | $25.26 | $213.98 |
| Revenue Next Year | $19.15 | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.26 | $2.72 |
| 52 Week High | $20.21 | $8.59 |
| Indicator | BDSX | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 37.12 |
| Support Level | $13.46 | N/A |
| Resistance Level | $16.38 | $3.36 |
| Average True Range (ATR) | 1.00 | 0.16 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 42.83 | 0.00 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.